The role trans-sclera MP-CPC as a primary treatment option in congenital glaucoma management

IF 0.9 Q4 OPHTHALMOLOGY

Expert Review of Ophthalmology Pub Date : 2022-07-04 DOI:10.1080/17469899.2022.2108790

Medhat A Bakr, Ussama A Moustafa, Majed Al-Subaie, Mohammed A Alfayyadh

{"title":"The role trans-sclera MP-CPC as a primary treatment option in congenital glaucoma management","authors":"Medhat A Bakr, Ussama A Moustafa, Majed Al-Subaie, Mohammed A Alfayyadh","doi":"10.1080/17469899.2022.2108790","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background Childhood glaucoma is considered one of the main causes of irreversible blindness. Primary congenital glaucoma (PCG) is a rare disease; however, in Middle East countries such as Saudi Arabia, the incidence is high. Research design and methods A retrospective study was conducted at Dhahran Eye Specialist Hospital from September 2016 to March 2020 to evaluate the efficacy and safety of transscleral micropulse cyclophotocoagulation (TS-MPCPC) as a primary procedure in congenital glaucoma and as an adjuvant to prepare the patient for ultimate surgical intervention. Emergent ophthalmic examination under sedation or general anesthesia was done to evaluate the presence of PCG features, measure the intraocular pressure (IOP), horizontal corneal diameter (HCD), and to evaluate the optic disc. Results Twenty-one eyes were included in the study. Cup to disc ratio (CDR) was not decreased postoperatively, and it was found statistically non-significant. There was statistically significant decrease in IOP and horizontal corneal diameter (HCD) (p < 0.001, 0.014), respectively. The mean reduction in IOP was 36%. The final IOP was between 5 and 21 mmHg in all cases. Qualified success was achieved in 17 (81%) eyes and 4 (19%) eyes had surgical failure. Conclusion TS-MPCPC might have effective and safe implications for congenital glaucoma patients.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17469899.2022.2108790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

ABSTRACT Background Childhood glaucoma is considered one of the main causes of irreversible blindness. Primary congenital glaucoma (PCG) is a rare disease; however, in Middle East countries such as Saudi Arabia, the incidence is high. Research design and methods A retrospective study was conducted at Dhahran Eye Specialist Hospital from September 2016 to March 2020 to evaluate the efficacy and safety of transscleral micropulse cyclophotocoagulation (TS-MPCPC) as a primary procedure in congenital glaucoma and as an adjuvant to prepare the patient for ultimate surgical intervention. Emergent ophthalmic examination under sedation or general anesthesia was done to evaluate the presence of PCG features, measure the intraocular pressure (IOP), horizontal corneal diameter (HCD), and to evaluate the optic disc. Results Twenty-one eyes were included in the study. Cup to disc ratio (CDR) was not decreased postoperatively, and it was found statistically non-significant. There was statistically significant decrease in IOP and horizontal corneal diameter (HCD) (p < 0.001, 0.014), respectively. The mean reduction in IOP was 36%. The final IOP was between 5 and 21 mmHg in all cases. Qualified success was achieved in 17 (81%) eyes and 4 (19%) eyes had surgical failure. Conclusion TS-MPCPC might have effective and safe implications for congenital glaucoma patients.

查看原文本刊更多论文

经巩膜MP-CPC作为先天性青光眼治疗的主要选择

摘要背景儿童期青光眼被认为是导致不可逆性失明的主要原因之一。原发性先天性青光眼是一种罕见的疾病；然而，在沙特阿拉伯等中东国家，发病率很高。研究设计和方法2016年9月至2020年3月，在达兰眼科专科医院进行了一项回顾性研究，以评估经巩膜微脉冲睫状体光凝术（TS-MPCPC）作为先天性青光眼的主要治疗方法和辅助治疗方法的有效性和安全性，为患者进行最终手术干预做好准备。在镇静或全身麻醉下进行紧急眼科检查，以评估PCG特征的存在，测量眼压（IOP）、水平角膜直径（HCD），并评估视盘。结果21只眼睛被纳入研究。术后杯盘比（CDR）没有下降，且无统计学意义。IOP和水平角膜直径（HCD）分别有统计学意义的降低（p＜0.001，0.014）。IOP平均降低36%。所有病例的最终眼压均在5至21毫米汞柱之间。17眼（81%）手术成功，4眼（19%）手术失败。结论TS-MPCPC可能对先天性青光眼患者具有安全有效的治疗作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Ophthalmology Health Professions-Optometry

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The worldwide problem of visual impairment is set to increase, as we are seeing increased longevity in developed countries. This will produce a crisis in vision care unless concerted action is taken. The substantial value that ophthalmic interventions confer to patients with eye diseases has led to intense research efforts in this area in recent years, with corresponding improvements in treatment, ophthalmic instrumentation and surgical techniques. As a result, the future for ophthalmology holds great promise as further exciting and innovative developments unfold.